SI

Business Context and Reporting Period

Company: Shoulder Innovations, Inc. (NYSE: SI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Shoulder Innovations is a commercial-stage medical technology company exclusively focused on shoulder surgical care. Its ecosystem includes advanced implant systems (InSet Glenoid and humeral stems) for anatomic (aTSA) and reverse (rTSA) shoulder arthroplasty, AI-enabled preoperative planning software (ProVoyance), and efficient instrument systems. The company targets hospitals and Ambulatory Surgery Centers (ASCs), leveraging a specialized commercial organization and independent distributors.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 49.6% to $47.3 million, driven by a 50% increase in procedure volume and an expansion in the number of customers. The average sales price remained stable at approximately $7,273.
• Profitability: The net loss widened significantly to $40.4 million from $15.6 million. This increase was primarily due to a $11.7 million non-cash charge related to the change in fair value of the Series E purchase option and a $2.2 million charge related to convertible notes, alongside increased operating expenses.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 58.7% to $54.8 million due to headcount growth, higher commissions, and increased professional fees. Research and development (R&D) expenses increased 72.2% to $7.7 million to support new product development.
• Capital Events: The company completed its Initial Public Offering (IPO) on August 1, 2025, raising net proceeds of approximately $64.2 million. All outstanding convertible preferred stock and convertible notes converted to common stock upon the IPO.
• Debt: The company maintains a $15.0 million term loan under the Trinity Loan Agreement. Interest expense decreased significantly due to higher interest income on marketable securities offsetting loan interest.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring operating losses for the foreseeable future as it scales its commercial organization, invests in R&D, and expands into international markets. The company believes its current cash and marketable securities ($124.3 million) are sufficient to fund operations for at least 12 months.
• Growth Strategy: Focus remains on increasing market share in ASCs, expanding the "commercial flywheel" of specialists and distributors, and launching new products including a fracture-specific system, revision solutions, and metal-hypersensitive implants. A robotics platform is also in development.
• Key Risks:
  • Profitability: History of significant net losses and an accumulated deficit of $97.4 million.
  • Supply Chain: Reliance on single-source suppliers for critical components (e.g., humeral stems, InSet Glenoid) creates vulnerability to supply disruptions.
  • Competition: Intense competition from large, established medical device companies with greater resources.
  • Regulatory: Extensive FDA oversight; failure to comply could result in recalls or loss of marketing authorization.
  • Legal: Ongoing patent infringement litigation with Catalyst OrthoScience Inc.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 50% procedure volume growth and the mix of hospital vs. ASC revenue.
• Non-GAAP Adjustments: Review the reconciliation of Net Loss to Adjusted EBITDA, specifically the $11.7 million fair value adjustment for the Series E purchase option, to understand core operational performance.
• Supply Chain Resilience: Assess the company's progress in qualifying alternative suppliers for its single-source components to mitigate production risks.
• Debt Covenants: Confirm continued compliance with the Trinity Loan Agreement covenants, particularly revenue milestones required for future tranches.
• Legal Exposure: Monitor the status of the patent litigation with Catalyst OrthoScience and potential financial impact.
• Related Party Transactions: Review the ongoing software license and consulting agreements with Genesis Software/Genesis Innovation, entities affiliated with the CEO, to ensure terms remain arm's length.